New research unveils a groundbreaking quintuple agonist that targets multiple pathways for effective treatment of obesity and ...

A compound comprising five agonists that together tackle weight loss, glucose reduction, insulin sensitization, and blood fat ...

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitors ...

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor ...

Quintuple agonists herald a new era in obesity care, unlocking the potential for powerful, sustained weight loss and improved ...

An announcement from Inventiva ( ($IVA) ) is now available. On October 1, 2025, Inventiva announced the appointment of Andrew Obenshain as the new ...

Mark Pruzanski, MD, Chairman of Inventiva’s Board of Directors, stated: “ With Phase 3 data on the horizon andand the preparation of potential marketing authorization applications underway, Inventiva ...

Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results ...

Cash and cash equivalents at €146.7 million including €24.6 million in short-term deposits1 as of June 30, 2025Receipt of the gross proceeds of ...

H.C. Wainwright analyst Ananda Ghosh believes Inventiva’s (IVA) lanifibranor “stands out” as the only pan PPAR agonist in Phase 3 with dual ...